Deutsch English Français

Contact

EP4028047

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP4028047

EP4028047 - NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS [Right-click to bookmark this link]
Status	Request for examination was made Status updated on 17.06.2022 Database last updated on 03.09.2024
Former	The international publication has been made Status updated on 20.03.2021
Most recent event Tooltip	29.01.2024	The date on which the examining division becomes responsible, has been established
	29.01.2024	Amendment by applicant
Applicant(s)	For all designated states Arbor Biotechnologies, Inc. 20 Acorn Park Drive, Tower 500 Cambridge, MA 02140 / US
	[2022/29]
Inventor(s)	01 / SCOTT, David, A. 20 Acorn Park Drive, Tower 500 Cambridge, MA 02140 / US
	02 / CHENG, David, R. 20 Acorn Park Drive, Tower 500 Cambridge, MA 02140 / US
	03 / YAN, Winston, X. 20 Acorn Park Drive, Tower 500 Cambridge, MA 02140 / US
	04 / DITOMMASO, Tia, M. 20 Acorn Park Drive, Tower 500 Cambridge, MA 02140 / US
	[2022/29]
Representative(s)	Maiwald GmbH Elisenhof Elisenstraße 3 80335 München / DE
	[N/P]
Former [2022/29]	Maiwald Patent- und Rechtsanwaltsgesellschaft mbH Elisenhof Elisenstraße 3 80335 München / DE
Application number, filing date	20863249.7	09.09.2020
	[2022/29]
	WO2020US49923
Priority number, date	US201962897859P	09.09.2019 Original published format: US 201962897859 P
	[2022/29]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2021050534
	Date:	18.03.2021
	Language:	EN
	[2021/11]
	Type:	A1 Application with search report
	No.:	EP4028047
	Date:	20.07.2022
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 18.03.2021 takes the place of the publication of the European patent application.
	[2022/29]
Search report(s)	International search report - published on:	US	18.03.2021
	(Supplementary) European search report - dispatched on:	EP	28.06.2023
Classification	IPC:	A61K38/46, A61K48/00, C07K19/00, C12N9/22, C12N15/00, C12N15/52	[2023/17]
	CPC:	C12N15/102 (EP,IL,KR); C12N9/22 (EP,IL,KR,US); C12N15/63 (EP,IL,KR); C12N1/20 (US); C12N15/11 (IL,US); C12N15/111 (US); (+) C12N15/113 (KR); C12N15/70 (US); C12N15/85 (US); C12N15/907 (EP,IL,KR,US); C12N5/0687 (US); C12Q1/6823 (US); C12N2310/20 (EP,IL,KR,US); C12N2800/10 (US); C12N2800/80 (US) (-)
	Former IPC [2022/29]	A61K38/46, C12N5/10, C12N9/22, C12N15/09, C12N15/113, C12N15/29
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/29]
Title	German:	NEUARTIGE, AUF CRISPR-DNA ABZIELENDE ENZYME UND SYSTEME	[2022/29]
	English:	NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS	[2022/29]
	French:	NOUVEAUX ENZYMES ET SYSTÈMES CIBLANT L'ADN CRISPR	[2022/29]
Entry into regional phase	04.04.2022	National basic fee paid
	04.04.2022	Search fee paid
	04.04.2022	Designation fee(s) paid
	04.04.2022	Examination fee paid
Examination procedure	04.04.2022	Examination requested [2022/29]
	29.01.2024	Amendment by applicant (claims and/or description)
	29.01.2024	Date on which the examining division has become responsible
Fees paid	Renewal fee
	04.04.2022	Renewal fee patent year 03
	29.08.2023	Renewal fee patent year 04
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[Y] - SHMAKOV SERGEY A. ET AL, "The CRISPR Spacer Space Is Dominated by Sequences from Species-Specific Mobilomes", MBIO, US, vol. 8, no. 5, doi:10.1128/mBio.01397-17, ISSN 2161-2129, (20171108), URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605939/pdf/mBio.01397-17.pdf, XP093032382 [Y] 1,2,4,5,7,8,11,12 * the whole document * DOI: http://dx.doi.org/10.1128/mBio.01397-17
		[Y] - CRAWLEY ALEXANDRA B. ET AL, "CRISPRdisco: An Automated Pipeline for the Discovery and Analysis of CRISPR-Cas Systems", vol. 1, no. 2, doi:10.1089/crispr.2017.0022, ISSN 2573-1599, (20180401), pages 171 - 181, THE CRISPR JOURNAL, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636876/pdf/crispr.2017.0022.pdf, XP093031030 [Y] 1,2,4,5,7,8,11,12 * the whole document * DOI: http://dx.doi.org/10.1089/crispr.2017.0022
		[Y] - ZHANG YA ET AL, "Benefits of Genomic Insights and CRISPR-Cas Signatures to Monitor Potential Pathogens across Drinking Water Production and Distribution Systems", vol. 8, doi:10.3389/fmicb.2017.02036, (20170101), page 2036, FRONTIERS IN MICROBIOLOGY, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654357/pdf/fmicb-08-02036.pdf, XP093031006 [Y] 1,2,4,5,7,8,11,12 * the whole document * DOI: http://dx.doi.org/10.3389/fmicb.2017.02036
		[Y] - DAVID BURSTEIN ET AL, "Benefits of Genomic Insights and CRISPR-Cas Signatures to Monitor Potential Pathogens across Drinking Water Production and Distribution Systems", NATURE, London, (20161222), vol. 542, no. 7640, doi:10.1038/nature21059, ISSN 0028-0836, pages 237 - 241, XP055533438 [Y] 1,2,4,5,7,8,11,12 * the whole document * DOI: http://dx.doi.org/10.1038/nature21059
		[Y] - BERNARD GUILLAUME ET AL, "Microbial Dark Matter Investigations: How Microbial Studies Transform Biological Knowledge and Empirically Sketch a Logic of Scientific Discovery", vol. 10, no. 3, doi:10.1093/gbe/evy031, (20180301), pages 707 - 715, GENOME BIOLOGY AND EVOLUTION, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830969/pdf/evy031.pdf, XP093031037 [Y] 1,2,4,5,7,8,11,12 * the whole document * DOI: http://dx.doi.org/10.1093/gbe/evy031
	International search	[A]US2004052799 (SMITH DOUGLAS [US], et al) [A] 1-4.48,49,73,74,121 * entire document *;
		[A]US2004216190 (KOVALIC DAVID K [US]) [A] 1-4, 48, 49, 73, 74, 121 * entire document *;
		[A]US2009202579 (COWMAN ALAN [AU], et al) [A] 1-4, 48, 49, 73, 74, 121 * entire document *;
		[A]US2013330335 (BREMEL ROBERT D [US], et al) [A] 1-4, 48, 49, 73, 74, 121 * entire document *;
		[A]US2014341918 (KURTIS JONATHAN [US], et al) [A] 1-4, 48, 49, 73, 74, 121 * entire document *;
		[A]WO2018071672 (UNIV COLORADO REGENTS [US], et al) [A] 1-4, 48, 49, 73, 74, 121* entire document *;
		[A]US2019002675 (SIDDIQUI MOHAMMAD NAHID [SA]) [A] 1-4, 48, 49, 73, 74,121 * entire document *

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p